MKI67 and hepatocellular carcinoma: In the anti-PD1 + TKI + AA group, Ki67 was significantly decreased expressed compared with anti-PD1 + TKI group (Fig. 6D and E).These evidence indicated that AA enhanced the inhibition of HCC when combined with anti-PD1 + TKI therapy in vivo.